R&D, risk, and performance in the spanish pharmaceutical industry: A strategic group analysis

International Journal of Innovation and Technology Management

Volumn 8, Issue 2, 2011, Pages 191-210

  Suárez Serrano, Eugenia ^a   Piña Mavarez, Enzo ^b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

firm performance; pharmaceutical industry; R D; risk; Spain; Strategic groups

Indexed keywords

EID: 84899798469     PISSN: 02198770     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0219877011002337     Document Type: Article

References (58)

1. Barney, J. and Hoskisson, R. (1990). Strategic groups: Untested assertions and research proposals, Managerial and Decision Economics, 11, 187-198.
2. Caves, R. E. and Porter, M. E. (1977). From entry barriers to mobility barriers: Conjectural decisions and contrived deterrence to new competition, Quarterly Journal of Economics, 91, 241-261.
3. Charalambous, C. and Gittins, J. (2008). Factors influencing the profitability of pharmaceutical research, R&D Management, 38, 2: 221-230.
4. Chi, T. (1994). Trading in strategic resources: Necessary conditions, transaction cost problems and choice of exchange structure, Strategic Management Journal, 15, 271-290.
5. Cool, K. and Dierickx, I. (1993). Rivalry, strategic groups and firm profitability, Strategic Management Journal, 14, 47-59.
6. Cool, K., Dierickx, I. and Martens, R. (1994). Asset stocks, strategic groups and rivalry, Daems, H. and Thomas, H. (eds.), Strategic Groups, Strategic Moves and Performance Oxford, Elsevier Science.
7. Cool, K. and Schendel, D. (1987). Strategic groups formation and performance: The case of the U.S. pharmaceutical industry, 1963-1982, Management Science, 33, 9: 1102-1124.
8. Cool, K. and Schendel, D. (1988). Performance differences among strategic groups members, Strategic Management Journal, 9, 207-223.
9. Davis, P. and Schul, P. (1993). Addressing the contingent effects of business unit strategic orientation on relationships between organizational context and business unit performance, Journal of Business Research, 27, 3: 183-200.
10. Dess, G. and Davis, P. (1984). Porters (1980) generic strategies as determinants of strategic group membership and organizational performance, Academy of Management Journal, 27, 467-488.
11. Dranove, D., Peteraf, M. and Shanley, M. (1998). Do strategic groups exist? An economic framework for analysis, Strategic Management Journal, 19, 1029-1044. (Pubitemid 128469360)
12. Farmaindustria (2006). La industria farmaceutica en cifras, Madrid, Farmaindustria.
13. Fiegenbaum, A. and Thomas, H. (1990). Strategic groups and performance: The U.S. insurance industry 1970-1984, Strategic Management Journal, 11, 197-215.
14. Frazier, G. L. and Howell, R. D. (1983). Business definition and performance, Journal of Marketing, 47, 59-67.
15. Gonzalez, E. and Ventura, J. (2002). How much do strategic group matter?, Review of Industrial Organization, 21, 55-71.
16. Gonzalez, E. and Ventura, J. (2006). Variedad estrategica y rentabilidad empresarial en la industria manufacturera, Revista de Econom?a Aplicada, XIV, 41: 67-90.
17. Grabowski, H. G. and Vernon, J. M. (2000). The determinants of pharmaceutical research and development expenditures, Journal of Evolutionary Economics, 10, 201-215.
18. Hair, J., Anderson, R., Tatham, R. and Black, W. (1999). Analisis Multivariante. Madrid, Prentice-Hall.
19. Harrigan, K. (1985). An application of clustering for strategic group analysis, Strategic Management Journal, 6, 55-73.
20. Hatten, K. and Hatten, M. (1987). Strategic groups, asymmetrical mobility barriers and contestability, Strategic Management Journal, 8, 329-342.
21. Howells, J., Gagliardi, D. and Malik, K. (2008). The growth and management of R&D outsourcing: Evidence from UK pharmaceuticals, R&D Management, 38, 2: 205-219.
22. Hunt, M. (1972). Competition in the Major Home Appliance Industry: 1960-1970. PhD Thesis, Harvard University.
23. Kong, Y. and Seldon, J. R. (2004). Pseudo-generic products and barriers to entry in pharmaceutical markets, Review of Industrial Organization, 25, 1: 71-86. (Pubitemid 39196608)
24. Kong, Y. and Seldon, J. R. (2006). Pseudo-generic products and barriers to entry in pharmaceutical markets: Reply, Review of Industrial Organization, 28, 2: 189-193.
25. Langley, A., Kakadadse, N. and Swailes, S. (2005). Grand strategies and strategic actions in the pharmaceutical industry 2001-2002, Technology Analysis & Strategic Management, 17, 4: 519-534. (Pubitemid 43135430)
26. Lawless, M. W., Bergh, D. D. and Wilsted, W. D. (1989). Performance variations among strategic group members: An examination of individual firm capability, Journal of Management, 15, 4: 649-661.
27. Leask, G. and Parker, D. (2006). Strategic group theory: Review, examination and application in the UK pharmaceutical industry, Journal of Management Development, 25, 4: 386-408. (Pubitemid 43548379)
28. Lee, J. (2003). Innovation and strategic divergence: An empirical analysis of the US pharmaceutical industry from 1920 to 1960, Management Science, 49, 2: 143-159.
29. Lewis, P. and Thomas, H. (1990). The linkage between strategy, strategic groups and performance in the U.K. retail grocery industry, Strategic Management Journal, 11, 385-397.
30. Mahlich, J. C. and Roediger-Schluga, T. (2006). The determinants of pharmaceutical expenditures: Evidence from Japan, Review of Industrial Organization, 28, 145-164.
31. Mas, J. and Gomez, J. (1992). Identificacion de grupos estrategicos en las cajas de ahorro espanolas, Revista Europea de Direccion y Econom?a de la Empresa, 1, 3: 9-28.
32. Mas, J., Nicolau, J. and Ruiz, F. (2005). Asymmetric rivalry between strategic groups: Response, speed of response and ex ante vs. ex post competitive interaction in the Spanish bank deposit market, Strategic Management Journal, 26, 713-745. (Pubitemid 40948525)
33. Mascarenhas, B. (1989). Strategic groups dynamics, Academy of Management Journal, 32, 2: 333-352.
34. Mascarenhas, B. and Aaker, D. A. (1989). Mobility barriers and strategic groups, Strategic Management Journal, 10, 475-485.
35. McGee, J. and Thomas, H. (1986). Strategic groups: Theory, research and taxonomy, Strategic Management Journal, 7, 141-160.
36. McGee, J., Thomas, H. and Pruet, M. (1995). Strategic groups and the analysis of market structure and industry dynamics, British Journal of Management, 6, 257-270. (Pubitemid 126018455)
37. McNamara, G., Deephouse, D. and Luce, A. (2003). Competitive positioning within and across strategic group structure: The performance of core, secondary and solitary firms, Strategic Management Journal, 24, 161-181.
38. Mehra, A. (1996). Resource and market based determinants of performance in the US banking industry, Strategic Management Journal, 17, 307-322. (Pubitemid 126458105)
39. Mittra, J. (2007). Life science innovation and the restructuring of the pharmaceutical industry: Merger, acquisition and strategic alliance behaviour of large firms, Technology Analysis & Strategic Management, 19, 3: 279-301. (Pubitemid 46823028)
40. Oster, S. (1982). Intraindustry structure and the ease of strategic change, Review of Economics and Statistics, 64, 376-383.
41. Oster, S. (1984). Modern Competitive Analysis. New York, Oxford University Press.
42. Pandian, J. R., Thomas, H., Furrer, O. and Bogner, W. (2006). Performance difference across strategic groups: An examination of financial market-based performance measures, Strategic Change, 15, 7-8: 373-383.
43. Pelayo, Y. and Vargas, A. (2004). Grupos estrategicos en el sector envasador del aceite de oliva, Revista Europea de Direccion y Econom?a de la Empresa, 13, 3: 93-114.
44. Porter, M. (1979). The structure within industries and companies performance, The Review of Economics and Statistics, 6, 1: 214-227.
45. Porter, M. (1980). Competitive Strategy: Techniques for Analysing Industries and Competitors, New York, Free Press.
46. Puig, J. (2004). Incentives and pharmaceutical reimbursement reforms in Spain, Health Policy, 67, 149-165.
47. Rama, R. (1999). Tasa de beneficio e innovacion en los grupos estrategicos de la industria alimentaria internacional, Cuadernos de Econom?a y Direccion de la Empresa, 4, 285-300.
48. Reger, R. and Huff, A. (1993). Strategic groups: A cognitive perspective, Strategic Management Journal, 14, 103-124.
49. Rumelt, R. P. (1984). Towards a strategic theory of the firm, Lamb, R. (ed.), Competitive Strategic Management, Englewood Cliffs, Prentice Hall.
50. Rodrigues, V. (2006). Pseudo-generic products and barriers to entry in pharmaceutical markets: Comment, Review of Industrial Organization, 28, 183-187.
51. Scherer, F. M., Harhoff, D. and Kukies, J. (2000). Uncertainty and the size distribution of rewards from innovation, Journal of Evolutionary Economics, 10, 175-200.
52. Scherer, F. M. (2004). The pharmaceutical industry-prices and progress, The New England Journal of Medicine, 351, 9: 927-932.
53. Soete, L. (1987). The impact of technological innovation on international trade patterns: The evidence reconsidered, Research Policy, 16, 2-4: 101-130.
54. Sola sola, J (2000). La industria farmaceutica espanyola: Estructura, estrategies i competitivitat, Document DEconom?a Industrial. Barcelona, Centre dEconom?a Industrial.
55. Thomas, H. and Venkatraman, N. (1988). Research on strategic groups: Progress and prognosis, Journal of Management Studies, 25, 6: 537-555.
56. Veliyath, R. and Ferris, S. (1997). Agency influences on risk reductions and operating performance: An empirical investigation among strategic groups, Journal of Business Research, 39, 219-230. (Pubitemid 127166847)
57. Wayne, D., Rajdeep, G. and Rui, W. (2008). Hybrid strategic groups, Strategic Management Journal, 29, 293-317.
58. Yeong-Wha, S. and Seung-Ho, K. (2007). Cluster characteristics and corporate performance: A case study of IT clusters in Korea, International Journal of Technology Management, 39, 3-4: 311-329